Bioprinting has often been presented in the media as something incredible that will maybe happen many years from now. The reality might be closer than we have imagined. The 3D bioprinting sector is booming and has been booming for a while.
A company called Rainbow Coral Corp wants to fully maximize the potential, and, through its subsidiary, Rainbow Biosciences, it has signed a partnership with Nano3D Biosciences (n3D), to further develop and market n3D’s BiO Assay.
Indeed, this is reportedly the world’s first commercially available 3D bioprinting system designed specifically for high throughput and high-content drug screening. An assay is an analytic procedure for assessing and measuring the presence of a drug or a biochemical substance in a cell or tissue.
n3D’s BiO Assay is a new type of assay that rapidly prints cells using magnetic 3D bioprinting.
Let’s have a look at a video that clarifies this:
Rainbow Biosciences is not the only player in the bioprinting market however, where more than a few quoted companies have seen their stock prices skyrocket in recent years. The most popular in the 3D printing world is probably Organovo, the only public “pure player” in bioprinting, which last year formed a partnership with CAD giant Autodesk to develop software for 3D tissue and organ design.
The other big players that Rainbow Biosciences parent company RBCC (which, by the way, was born as a retail fish store and coral growing facility for biological research) is facing are Biogen Idec, Abbott Laboratories and Amgen Inc.
